S-1 · resale registration
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
DilutionScan read 47 of CDT Equity Inc.'s SEC filings and found 14 warrant series, 7 convertibles, 1 ATM program, 1 equity line, 7 shelf registrations, 1 S-1 registration and 10 completed offerings on file for CDT. The latest dilution event on file is an offering on Oct 22, 2026. Analysis updated Oct 27, 2026.
CDT
Two reverse splits and delisting risk
CDT Equity is a clinical-stage biotech generating $0 revenue and burning cash rapidly. FY 2025 losses hit $39.2M with no revenue to offset the burn. The balance sheet shows $390M in cash against $1.29B in debt, while the market values the entire company at just $5M.
Raise routes on file: active ATM + effective shelf + effective S-1 + active equity line · latest dilution event 12 days ago
The dominant contractual driver and its mechanism, then each further driver ranked.
Oct 22, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Shares outstanding, potential dilution and cash over time
Issued 2026
Proposed maximum
Shares registered
Issued 2026
Shares Underlying
Exercise Price
Issued 2026
Shares Underlying
Exercise Price
Issued 2026
Shares Underlying
Exercise Price
Issued 2026
Shares Underlying
Exercise Price
Issued 2026
Shares Underlying
Exercise Price
Issued 2026
Shares Underlying
Exercise Price
Principal
Conversion Price
Principal
Conversion Price
Principal
Conversion Price
Principal
Conversion Price
Principal
Conversion Price
Principal
Conversion Price
Issued 2024
Total capacity
Sold to date
Issued 2026
Commitment
Sold to date
Issued 2024
Total capacity
Remaining
Issued 2024
Total capacity
Remaining
Issued 2025
Total capacity
Remaining
Issued 2025
Total capacity
Remaining
Issued 2025
Total capacity
Remaining
Issued 2026
Total capacity
Remaining
Issued 2026
Gross proceeds
Price per share
Gross proceeds
Price per share
Issued 2026
Gross proceeds
Price per share
Issued 2026
Gross proceeds
Price per share
Issued 2026
Gross proceeds
Price per share
Issued 2026
Gross proceeds
Price per share
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
DilutionScan ProEvery instrument in full · $59/mo
Covered companies in Biotechnology. All tickers A to Z